This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down
by Zacks Equity Research
Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.
How Are Biotech ETFs Reacting to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Ligand (LGND) Q1 Earnings Beat, OmniAb Spin-Off on Track
by Zacks Equity Research
Ligand (LGND) reports encouraging first-quarter 2022 numbers by beating estimates on both counts. However, Captisol sales get hurt by lower demand for COVID-19 therapies.
Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News
by Zacks Equity Research
Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales
by Zacks Equity Research
Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.
Gilead Sciences (GILD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 19.77% and 6.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
by Zacks Equity Research
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News
by Zacks Equity Research
Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.
Should You Buy Gilead (GILD) Ahead of Earnings?
by Zacks Equity Research
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Healthcare ETFs in Focus Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
Gilead (GILD) to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) first-quarter 2022 results.
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $63.75, moving +0.24% from the previous trading session.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More
by Zacks Equity Research
Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $62.06 in the latest trading session, marking a +0.7% move from the prior day.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
by Zacks Equity Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
The Zacks Analyst Blog Highlights Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals
by Zacks Equity Research
Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals are part of top Analyst article.
Biotech Stock Roundup: VIR Down on Regulatory News, BMY Offers Updates & More
by Zacks Equity Research
Regulatory and pipeline news from Vir Biotechnology (VIR) and Bristol Myers (BMY) are a few key highlights from the biotech sector during the past week.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $59.75, marking a -1.52% move from the previous day.
Roche (RHHBY) Actemra Application Receives Priority Review
by Zacks Equity Research
Roche (RHHBY) sBLA is seeking approval for the intravenous formulation of arthritis drug Actemra accepted and granted Priority Review in the United States.
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
by Zacks Equity Research
Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.
VIR Stock Gains on News of Inclusion in the S&P SmallCap 600
by Zacks Equity Research
Vir Biotechnology (VIR) shares gain as the company is set to join the S&P SmallCap 600 effective prior to the opening of trading on Monday, Apr 4.